2022-07-23 02:35:00
Women’s Healthcare Market Poised for Growth
The women’s healthcare market is experiencing significant expansion, fueled by chronic health conditions, government initiatives, and a rising demand for contraceptives.
- The market is driven by increasing chronic health conditions, government policies, and contraceptive demand.
- North America is the largest and fastest-growing regional market.
- Prolia is a key segment experiencing rapid growth.
What’s driving the growth in the women’s healthcare market? The expansion is primarily due to the increasing incidence of chronic health conditions among women, government efforts to control population growth, and the rising need for contraceptives to prevent unintended pregnancies. Research and development by major players in the industry for advanced product development also play a key role in this growth.
The study involved four major steps to estimate the current size of the global women’s healthcare market. Extensive research was conducted to gather information. The findings, assumptions, and sizing values were then validated with industry experts. Both top-down and bottom-up approaches were used to estimate the total market size and to determine the size of various sub-segments.
Market Size Estimation Methodology
Both top-down and bottom-up approaches were employed to determine and validate the total market size. The methodology included identifying key players through secondary research. Revenue generated from product sales in various regions by leading players was aggregated to determine market value at the global level. All percentage shares, splits, and breakdowns were determined from secondary sources and verified through primary sources.
Regional Market Dynamics
North America is the largest and fastest-growing regional market for women’s healthcare. Factors contributing to this growth include the rising median age of first-time pregnancies and the increasing prevalence of conditions like PCOS and postmenopausal osteoporosis. Further growth is supported by growing awareness about contraceptives, easy access to modern contraception, and increased healthcare spending.
Key players in the global Women’s Health Care Market include Bayer AG (Germany), Allergan (Dublin), Merck & Co. (US), Pfizer Inc. (US), Amgen (US), Agile Therapeutics Inc. (US), Ferring Pharmaceuticals (US), Mylan N.V. (US), Lupin (India), Blairex Laboratories (US), Apothecus Pharmaceutical (US), Eli Lilly And Company (US), Novartis AG (Switzerland), and Johnson & Johnson (US).
Amgen’s Role
Amgen (US) is a leading provider in the women’s healthcare market, with a strong focus on the US and Europe. The company offers Prolia and Xgeva for osteoporosis treatment in postmenopausal women, with significant year-on-year growth. Amgen’s EVENITY, for treating osteoporosis, is in phase 3 development, in collaboration with UCB (Belgium). The company’s brand recognition and product innovation have been crucial for maintaining its market position.
The women’s health care market is segmented by drug, including EVISTA, XGEVA, Prolia, Mirena, Zometa, Reclast/Aclasta, Minastrin 24 Fe, NuvaRing, FORTEO, Premarin, ACTONEL, and ORTHO-TRI-CY LO (28). Prolia is the largest and fastest-growing segment, primarily due to increased unit demand and the rising prevalence of postmenopausal osteoporosis in the US.
